The impact of ferric derisomaltose on cardiovascular and noncardiovascular events in patients with anemia, iron deficiency, and heart failure with reduced ejection fraction.
No Thumbnail Available
Authors
Spencer, Charles
Issue Date
2024-05-01
Type
Article
Peer-Reviewed Publication
Peer-Reviewed Publication
Keywords
Aged
COVID-19
Female
Ferric compounds
Heart failure
Iron-deficiency anaemia
Male
Maltose
Middle aged
Multicentre study
Randomised controlled trial
Peer-reviewed article
Quality of life
Stroke volume
Treatment outcome
COVID-19
Female
Ferric compounds
Heart failure
Iron-deficiency anaemia
Male
Maltose
Middle aged
Multicentre study
Randomised controlled trial
Peer-reviewed article
Quality of life
Stroke volume
Treatment outcome
Journal
Jouornal of Cardiac Failure
Volume
30
Issue
5
Alternative Title
Abstract
Background: In some countries, intravenous ferric derisomaltose (FDI) is only licensed for treating iron deficiency with anemia. Accordingly, we investigated the effects of intravenous FDI in a subgroup of patients with anemia in the IRONMAN (Effectiveness of Intravenous (IV) Iron Treatment Versus Standard Care in Patients With Heart Failure and Iron Deficiency) trial.
Method and results: IRONMAN enrolled patients with heart failure, a left ventricular ejection fraction of ≤45%, and iron deficiency (ferritin <100 µg/L or transferrin saturation of <20%), 771 (68%) of whom had anemia (hemoglobin <12 g/dL for women and <13 g/dL for men). Patients were randomized, open label, to FDI (n = 397) or usual care (n = 374) and followed for a median of 2.6 years. The primary end point, recurrent hospitalization for heart failure and cardiovascular death, occurred less frequently for those assigned to FDI (rate ratio 0.78, 95% confidence interval 0.61-1.01; P = .063). First event analysis for cardiovascular death or hospitalization for heart failure, less affected by the coronavirus disease 2019 pandemic, gave similar results (hazard ratio 0.77, 95% confidence interval 0.62-0.96; P = .022). Patients randomized to FDI reported a better Minnesota Living with Heart Failure quality of life, for overall (P = .013) and physical domain (P = .00093) scores at 4 months.
Conclusions: In patients with iron deficiency anemia and heart failure with reduced left ventricular ejection fraction, intravenous FDI improves quality of life and may decrease cardiovascular events.
Citation
Ray R, Ford I, Cleland JGF, Graham F, Ahmed FZ, Al-Mohammad A, Cowburn PJ, Critoph C, Kalra PA, Lane RE, Ludman A, Pellicori P, Petrie MC, Robertson M, Seed A, Squire I, Kalra PR; INVESTIGATORS; CLINICAL TRIALS UNIT AND DATA AND STATISTICAL CENTRE; NURSING AND ADMINISTRATIVE SUPPORT; SPONSOR SUPPORT. The Impact of Ferric Derisomaltose on Cardiovascular and Noncardiovascular Events in Patients With Anemia, Iron Deficiency, and Heart Failure With Reduced Ejection Fraction. J Card Fail. 2024 May;30(5):682-690. doi: 10.1016/j.cardfail.2023.10.006. Epub 2023 Nov 4. PMID: 37926238; PMCID: PMC11096866.